Premium Grade | UK Supply | Research Peptide | COA Certified | >99% Purity | Worldwide Delivery

(Tripeptide, 3 amino acids)

Brief Summary

Cartalax is a synthetic short-chain peptide studied in laboratory settings for its relationship with cartilage biology, extracellular matrix regulation and cellular ageing pathways. Also identified by the sequence AED, Cartalax contains three amino acids: alanine, glutamic acid and aspartic acid. The peptide belongs to the Khavinson-class group of short peptide bioregulators investigated for tissue-associated molecular activity. Research has focused particularly on fibroblast responses, cartilage-related cellular processes, matrix metalloproteinase activity and gene-expression markers connected to extracellular matrix maintenance. Cartalax has also been examined in experimental models involving cellular proliferation, senescence-associated signalling and connective tissue regulation. Within scientific research catalogues, Cartalax is valued for in vitro and preclinical investigation involving chondrocyte biology, fibroblast activity, matrix turnover and short-peptide bioregulation. Its defined three-amino-acid sequence supports structured laboratory study, analytical characterisation and reproducible peptide research within professional scientific environments.

Product Overview

Cartalax is a laboratory-grade synthetic tripeptide developed for controlled research into cartilage-associated biology, connective tissue signalling and short-peptide regulation. Its amino-acid sequence, Ala–Glu–Asp, is commonly abbreviated as AED and contains one non-polar residue and two acidic residues. This compact molecular structure allows researchers to investigate how short peptide sequences may interact with cellular components and influence tissue-associated gene-expression pathways. Cartalax has been examined in fibroblast and cartilage-related experimental models, with particular attention given to cellular proliferation, apoptosis-associated markers, extracellular matrix organisation and age-related cellular changes. The peptide is also relevant to comparative studies involving other Khavinson-class bioregulators, including Cardiogen, Vesugen and Epitalon. Its defined composition, low molecular weight and reproducible molecular characteristics support controlled investigation into peptide bioregulation, cartilage cell signalling, connective tissue responses and extracellular matrix-associated pathways.

Scientific Background

From a molecular science perspective, Cartalax is studied as a short peptide bioregulator associated with cartilage, fibroblast and extracellular matrix research. Experimental studies have examined its relationship with cellular proliferation markers, apoptosis-associated signalling and matrix metalloproteinase activity under controlled laboratory conditions. Matrix metalloproteinases are enzymes involved in extracellular matrix turnover, making their expression relevant to research examining collagen organisation and cartilage-associated tissue changes. Cartalax has also been investigated in relation to transcription factors, cellular stress responses and senescence-associated molecular markers. Broader short-peptide research proposes that tripeptides may interact with selected DNA regions and contribute to the regulation of tissue-associated genes, although these proposed mechanisms require continued independent investigation. Cartalax therefore provides a compact molecular tool for examining short-peptide signalling, fibroblast behaviour, cartilage-related cellular processes and the relationship between defined amino-acid sequences and extracellular matrix regulation.

Research Applications

Cartalax is applied in laboratory research across peptide science, cartilage biology, connective tissue investigation and cellular bioregulation. Researchers use the peptide to examine fibroblast responses, chondrocyte-associated signalling, extracellular matrix turnover, collagen-related markers and cellular ageing processes under controlled experimental conditions. Additional research applications include analysis of matrix metalloproteinase expression, proliferation-associated pathways, apoptosis markers, transcription-factor activity and stress-induced cellular responses. Cartalax may also be used to investigate proposed peptide-DNA interactions, tissue-associated gene regulation and the influence of defined amino-acid sequences on cellular communication. Its three-residue structure supports research into peptide simplification, sequence-specific signalling, molecular recognition and structure-activity relationships. These applications contribute to a broader understanding of short-peptide biology and how compact synthetic sequences may be examined in relation to cartilage and connective tissue regulation. Cartalax is supplied as a research compound for analytical, in vitro and controlled preclinical investigation only.

Technical Specifications

Contents: 20mg Cartalax
Form: Lyophilised powder
Purity: >99% (HPLC Verified)
Molecular Formula: C₁₂H₁₉N₃O₈
Molecular Weight: 333.29 g/mol
Sequence: Alanine–Glutamic Acid–Aspartic Acid
Peptide Length: 3 amino acids
pH Range: Refer to batch-specific documentation and experimental protocol
Storage: Store between 2°C and 8°C in accordance with the product documentation

Note: Reconstitute with Bacteriostatic Water

Explore Related Research Compounds
Continue exploring related laboratory research products from BioPlex Peptides.

View BPC-157 10mg Research Compound ⟶
View KVP 10mg Research Compound ⟶
View  TB500 10mg Research Compound ⟶

Research Preparation and Storage
Access BioPlex solutions, calculation tools and storage guidance for accurate and consistent laboratory preparation.

View Reconstitution Solutions ⟶
Use the Peptide Reconstitution Calculator ⟶
Read the Peptide Types and Storage Guide ⟶

Explore Related Research Articles

Continue your research with detailed BioPlex articles covering compound structures, scientific mechanisms and laboratory research pathways.

Disclaimer

For research purposes only. Not for human consumption